Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham P Collins

Showing results (31-40 of 164) with videos related to

Pageof 17
Sort By:
Blood|October 19, 2023
Tackling PD1i resistance in Hodgkin lymphomaGraham P Collins
Frontiers in Oncology|January 30, 2023
Older patients with Hodgkin Lymphoma: Walking the tightrope of efficacy and toxicityAisling Barrett, Graham P Collins
Current Oncology Reports|June 13, 2022
Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma PathwayXiao-Yin Zhang, Graham P Collins
British Journal of Haematology|April 1, 2015
Immune checkpoint inhibition in lymphoid diseaseToby A Eyre, Graham P Collins
Therapeutic Advances in Hematology|November 4, 2021
Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphomaAlexandros Rampotas, Gina Sangha, Graham P Collins
Journal of Medical Economics|April 12, 2014
Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United KingdomSimon Rule, Graham P Collins, Kunal Samanta
Current Hematologic Malignancy Reports|June 30, 2019
Front-Line Treatment of High Grade B Cell Non-Hodgkin LymphomaMurali Kesavan, Toby A Eyre, Graham P Collins
The Lancet. Haematology|July 30, 2021
Sequencing therapies in Hodgkin lymphomaElizabeth H Phillips, Graham P Collins, Kate Cwynarski
British Journal of Hospital Medicine (London, England : 2005)|November 14, 2013
Classical Hodgkin's lymphoma: past, present and future perspectivesToby A Eyre, Andrew J King, Graham P Collins
British Journal of Haematology|February 17, 2021
Care of haematology patients in an overwhelmed healthcare systemJohn Willan, Andrew King, Nicola Bienz, et al.
Pageof 17

Showing results (31-40 of 164) with videos related to

Sort By:
Pageof 17
Blood|October 19, 2023
Tackling PD1i resistance in Hodgkin lymphomaGraham P Collins
Frontiers in Oncology|January 30, 2023
Older patients with Hodgkin Lymphoma: Walking the tightrope of efficacy and toxicityAisling Barrett, Graham P Collins
Current Oncology Reports|June 13, 2022
Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma PathwayXiao-Yin Zhang, Graham P Collins
British Journal of Haematology|April 1, 2015
Immune checkpoint inhibition in lymphoid diseaseToby A Eyre, Graham P Collins
Therapeutic Advances in Hematology|November 4, 2021
Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphomaAlexandros Rampotas, Gina Sangha, Graham P Collins
Journal of Medical Economics|April 12, 2014
Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United KingdomSimon Rule, Graham P Collins, Kunal Samanta
Current Hematologic Malignancy Reports|June 30, 2019
Front-Line Treatment of High Grade B Cell Non-Hodgkin LymphomaMurali Kesavan, Toby A Eyre, Graham P Collins
The Lancet. Haematology|July 30, 2021
Sequencing therapies in Hodgkin lymphomaElizabeth H Phillips, Graham P Collins, Kate Cwynarski
British Journal of Hospital Medicine (London, England : 2005)|November 14, 2013
Classical Hodgkin's lymphoma: past, present and future perspectivesToby A Eyre, Andrew J King, Graham P Collins
British Journal of Haematology|February 17, 2021
Care of haematology patients in an overwhelmed healthcare systemJohn Willan, Andrew King, Nicola Bienz, et al.
Pageof 17